Background-Subjects who convert to type 2 diabetes mellitus have increased cardiovascular risk factors relative to nonconverters. However, it is not known whether these atherogenic changes in the prediabetic state are predominantly due to insulin resistance, decreased insulin secretion, or both. Methods and Results-We examined this issue in the 7-year follow-up of the San Antonio Heart Study, in which 195 of 1734 subjects converted to type 2 diabetes. At baseline, converters had significantly higher body mass index, waist circumference, triglyceride concentration, and blood pressure and lower HDL cholesterol than nonconverters. Atherogenic changes in converters were markedly attenuated (and no longer significant) after adjustment for the homeostasis model assessment of insulin resistance (HOMA IR, a surrogate for insulin resistance); in contrast, the differences in risk factors between converters and nonconverters increased after adjustment for the ratio of early insulin increment to early glucose increment (⌬I 30-0 /⌬G 30-0 ) during an oral glucose tolerance test (a surrogate for insulin secretion). We also compared converters who had a predominant insulin resistance (high HOMA IR and high ⌬I 30-0 /⌬G 30-0 ) (nϭ56) and converters who had a predominant decrease in insulin secretion (low HOMA IR and low ⌬I 30-0 /⌬G 30-0 ) (nϭ31) with nonconverters (nϭ1539). Only the converters who were insulin resistant had higher blood pressure and triglyceride levels and lower HDL cholesterol levels than nonconverters. Conclusions-Our data suggest that atherogenic changes in the prediabetic state are mainly seen in insulin-resistant subjects and that strategies to prevent type 2 diabetes might focus on insulin-sensitizing interventions rather than interventions that increase insulin secretion because of potential effects on cardiovascular risk. (Circulation. 2000;101:975-980.)
T ype 2 diabetes mellitus is associated with a marked increase in coronary heart disease (CHD). [1] [2] [3] The relationship between glycemia and CHD in type 2 diabetes has been controversial, with some studies showing strong associations, 4 some weak associations, 5 and others no associations. 6 The recently published United Kingdom Prospective Diabetes Study (UKPDS) found a greater benefit of glycemic control on microvascular events than for CHD or stroke. 7 One explanation for the relatively weak effect of glycemia on CHD in type 2 diabetes might be the existence of a highly atherogenic state before the onset of diabetes. 8 Increased risk factors for CHD before the onset of type 2 diabetes have been shown in several populations, including Israelis, 9 elderly American subjects, 10 elderly Finnish subjects, 11 Mexican American subjects, 12 and Pima Indians. 13 The causes of increased atherogenicity of the prediabetic state are not fully understood. Both insulin resistance (measured directly 14 or through surrogates such as fasting insulin [15] [16] [17] ) and decreased insulin secretion 18 -21 predict the development of type 2 diabetes. It is not known whether the increased atherogenicity of the prediabetic state is primarily due to increased insulin resistance or decreased insulin secretion, although increased resistance may be likely given the amount of information on the insulin-resistance syndrome. 22, 23 In this report, we examine whether insulin resistance or decreased insulin secretion is responsible for the atherogenic prediabetic state. In particular, we were interested in whether cardiovascular risk factors were similar in prediabetic subjects who had a predominant insulin-secretory defect (normal insulin sensitivity but low insulin-secretory response) as opposed to subjects with a predominant insulin-resistance defect (insulin resistant but with good insulin-secretory response 
Methods
The San Antonio Heart Study is a population-based study of diabetes and cardiovascular disease in Mexican American and non-Hispanic whites. From 1984 to 1988, we randomly selected households from low-income (barrio), middle-income (transitional), and high-income (suburban) census tracts in San Antonio, Tex. 26 All men and nonpregnant women aged 25 to 64 years who resided in the randomly sampled households were eligible to participate. Mexican Americans were defined as individuals whose ancestry derived from a Mexican national origin. Detailed descriptions of this study have been published previously. 26 This study was approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio. All subjects gave informed consent. Beginning in October 1991, we began a 7-year follow-up of the cohort. 20 The results in this report are based on risk factors for the development of type 2 diabetes. Subjects with diabetes at the baseline examination were excluded from this report.
At the baseline and follow-up visits, blood specimens were obtained after a 12-to 14-hour fast for determination of plasma glucose, serum insulin, and serum lipids and lipoproteins. Methods for determination of lipids and lipoproteins and glucose have been described previously. 20 We measured serum insulin with a solidphase radioimmunoassay (Diagnostic Products Corporation) that shows a relatively high degree of cross-reactivity with proinsulin (Ϸ70% to 100%). 26 A 75-g oral glucose load (Orangedex; Custom Laboratories) was administered, and blood specimens were obtained 30 minutes, 1 hour, and 2 hours later for plasma glucose and serum insulin concentrations. At the follow-up examination, post-glucoseload specimens were obtained only at the 2-hour time point. Diabetes was diagnosed according to World Health Organization (WHO) criteria. 27 Subjects who did not meet WHO plasma glucose criteria but who were undergoing treatment with oral antidiabetic agents or insulin were considered to have diabetes. In this report, we use the homeostasis model of insulin resistance (HOMA IR) as a measure of insulin resistance 28 -30 and ⌬I 30-0 /⌬G 31 as a measure of insulin secretion (early secretory response to an oral glucose load). The formula for the HOMA IR model 28 follows:
HOMA IRϭFasting insulin (U/mL)ϫfasting glucose (mmol/L) 22.5
The correlation of HOMA IR and fasting insulin in nondiabetic subjects is 0.98. Anthropometric measurements (height, weight, and waist and hip circumferences) were made after participants had removed their shoes and upper garments and donned an examination gown. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters squared). Waist circumference was chosen as a measure of central adiposity.
The systolic (first phase) and diastolic (fifth phase) blood pressures were measured to the nearest even digit by use of a randomzero sphygmomanometer (Hawksley-Gelman). Three readings were recorded for each individual, and the average of the second and third readings was defined as the patient's blood pressure.
Statistical analyses included ANCOVA performed with SAS statistic software. Two-way ANCOVA was done initially with conversion to diabetes and ethnicity (Mexican American versus non-Hispanic whites as the grouping variable). The P value for these interaction terms (ethnicity times conversion status) were all Ͼ0.100. Because there was no evidence of different effect of conversion status by ethnicity on variables of interest (ie, triglycerides or blood pressure), we pooled the ethnic groups with control for ethnicity to increase statistical power and to simplify the analysis. One-way ANCOVA was done with conversion to diabetes as the main effect (Tables 1 and 2 ). Additional analysis was done with 2-way ANCOVA among the converters to diabetes by dividing subjects by their insulinresistance or insulin-secretion status at baseline (HOMA IR above and below median of 3.0 and insulin secretion [⌬I 30-0 /⌬G 30-0 in pmol/mmol] above and below median of 155.6 pmol/L) ( Table 3 ). The median was based on the overall nondiabetic population at baseline. Finally, 1-way ANCOVAs (with pairwise contrasts) were done with conversion to diabetes as the dependent variable to compare subjects with predominant insulin resistance (above median for both HOMA IR and ⌬I 30-0 / ⌬G 30-0 ) and subjects with a predominant insulin-secretory defect (below median for both fasting insulin and ⌬I 30-0 /⌬G 30-0 ) with subjects who did not convert to type 2 diabetes ( Figure 2 ). Triglyceride, fasting insulin, HOMA IR, and ⌬I 30-0 /⌬G 30-0 were transformed to improve the skewness and kurtosis of their distribution for statistical testing. These variables were both back-transformed for presentation in the tables. All probability values are 2-sided. Table 1 shows the baseline characteristics of subjects by conversion to diabetes, adjusted for age, sex, and ethnicity. Fasting insulin and HOMA IR were higher and ⌬I 30-0 /⌬G was lower in converters to diabetes than in subjects who remained nondiabetic. Subjects who converted to diabetes had greater obesity and an unfavorable body fat distribution, higher blood pressure, higher prevalence of hypertension, higher glucose levels, higher triglyceride levels, and lower HDL cholesterol than subjects who did not convert to diabetes. Total and LDL cholesterol levels and smoking status were similar in converters and nonconverters.
Results
As shown in Table 2 (model A), after further adjustment for fasting glucose and waist circumference, converters continued to have higher blood pressure and higher triglyceride levels and lower HDL cholesterol levels than subjects who did not convert to diabetes. Table 2 shows the effects of additional adjustment for HOMA IR (a surrogate for insulin resistance) (model B) versus the effect of adjustment for ⌬I 30-0 /⌬G 30-0 (model C), a surrogate for insulin secretion. Adjustment for HOMA IR attenuated the differences between converters and nonconverters, making them no longer statistically significant. In contrast, after adjustment for insulin secretion (⌬I 30-0 /⌬G ), the differences between converters and nonconverters to type 2 diabetes remained statistically significant.
We next categorized the subjects simultaneously by insulin resistance (above and below the median for HOMA IR in the overall nondiabetic population at baseline) and insulin secretion (above and below the median for ⌬I 30-0 /⌬G 30-0 ). The incidence of type 2 diabetes by insulin resistance and secretion categories is shown in Figure 1 . As expected, subjects with the highest rate of developing type 2 diabetes had both insulin resistance and decreased insulin secretion (31.8% in 7 years), and the lowest rate was in subjects who were insulin sensitive with good secretory capacity (1.0%). Subjects with insulin resistance but good insulin secretion had a higher conversion rate than subjects with low insulin secretion who were insulin sensitive (11.0% versus 6.2%). These results are similar to those presented for a smaller cohort of Mexican Americans only. 20 We also characterized the distribution of insulin resistance and secretory effects of converters to diabetes and insulin secretion. Fifty-four percent of converters had both an insulin secretory defect and were insulin resistant compared with 1.5% of converters who were insulin sensitive with good secretion at baseline. The subjects who were predominantly insulin resistant with good insulin secretion at baseline comprised 28.7% of all converters to type 2 diabetes compared with 15.9% of subjects who had low insulin secretion but were insulin sensitive (predominantly insulin sensitive). Table 3 shows anthropometric and cardiovascular risk factors by insulin resistance and secretion categories. Insulin resistance was associated with higher BMI, greater waist circumference, and higher blood pressure and triglyceride levels and lower HDL cholesterol levels. Insulin secretion was not related to anthropometric or cardiovascular risk factors. Fasting and 2-hour glucose levels were similar in each group. Additional adjustment for BMI or waist circumference did not appreciably change these results (data not shown). Figure 2 compares the triglyceride and HDL levels and systolic blood pressure in converters to type 2 diabetes with predominant insulin resistance (high HOMA IR and high ⌬I 30-0 /⌬G 30-0 ), converters with a predominant insulin-secretory defect (low ⌬I 30-0 /⌬G 30-0 and low HOMA IR), and nonconverters to type 2 diabetes. Among converters to diabetes, the only subjects with adverse cardiovascular risk factors (high systolic blood pressure and triglyceride levels and low HDL cholesterol levels) were converters to diabetes with high IR and ⌬I 30-0 /⌬G 30-0 (insulin-resistant subjects).
Subjects who converted to diabetes but had predominant insulin resistance had a BMI 3 to 4 kg/m 2 higher than subjects who did not convert to diabetes or who converted to diabetes but had a predominant insulin-secretory defect. Adjustment for differences in BMI somewhat attenuated the differences in lipoproteins or blood pressure (Ϸ30%), but converters to diabetes who had predominant insulin resistance continued to have significantly more atherogenic risk factors than the other 2 groups (PϽ0.01).
Discussion
We have confirmed that prediabetic subjects have increased cardiovascular risk factors at baseline relative to subjects who do not convert to type 2 diabetes. These results extend previous results in earlier reports in a variety of ethnic groups, 9 -13 including reports on smaller groups of Mexican Americans in the San Antonio Heart Study. 12 The increased atherogenicity of the prediabetic state was due only in part to differences in overall adiposity and upper-body adiposity between the converters and nonconverters to type 2 diabetes (Table 1) . More interesting is whether the atherogenic differences in prediabetic subjects are due to increased insulin resistance, decreased insulin secretion, or both. To address this issue, we used 2 different approaches: that of statistical adjustment (Tables 1 and 2 ) and that of stratification (Table 3 and Figure  2 ). After adjustment for HOMA IR, the differences between converters and nonconverters were attenuated and were no longer statistically significant. In contrast, after adjustment for ⌬I 30-0 /⌬G 30-0 (a surrogate for decreased secretory response that has been shown to be a significant predictor of type 2 diabetes in this cohort 20 ), the differences between converters and nonconverters actually widened (Table 2) .
Subjects who converted to diabetes but were insulin resistant had significantly higher triglyceride levels, systolic blood pressure, and diastolic blood pressure and lower HDL cholesterol levels than subjects who converted to diabetes but who were insulin sensitive. The 2 groups of converters to type 2 diabetes (predominantly insulin-resistant versus insulinsensitive converters) had similar values for both fasting and 2-hour glucose levels, but the insulin-resistant converters were more obese (Table 3) . After additional adjustment for BMI (data not shown), insulin-resistant converters to type 2 diabetes still had worse cardiovascular risk factors than insulin-sensitive converters. Interestingly, insulin-sensitive converters to type 2 diabetes had triglyceride and HDL cholesterol levels and systolic blood pressure similar to those of subjects who remained nondiabetic at baseline.
We have thus identified different subgroups of converters to type 2 diabetes with markedly different patterns of cardiovascular risk factors. The implication is that the subjects who were insulin resistant and converted to diabetes would have more cardiovascular disease than the insulin-sensitive subjects who converted to diabetes.
We should point out that the differences in lipids (triglyceride 0.9 mmol and HDL cholesterol 0.24 mmol) and systolic blood pressure (6.5 mm Hg) (Table 3) are actually larger than the differences between diabetic (nϭ303) and nondiabetic (nϭ2564) subjects in the San Antonio Heart Study (for diabetic versus nondiabetic subjects, respectively: triglyceride 2.3 versus 1.6 mmol/L, a 0.7 mmol/L difference; HDL 25 ). Similarly, there are prevention trials involving insulin secretagogues (NANSY [sulfonylurea {Amaryl}]). If our results are correct, they suggest that the use of a sulfonylurea to prevent diabetes might increase the risk of CHD (or at least prove less beneficial) than the use of insulin-sensitizing agents. The effects of different modalities for the prevention of diabetes on CHD will be particularly informative. However, improvement in glycemic control in diabetic subjects by sulfonylurea has led to reduction in insulin resistance in diabetic subjects, 32 suggesting that the differential between insulin sensitizers and insulin secretagogues with respect to cardiovascular risk factors could be overestimated in epidemiological studies such as the present report. However, whether insulin secretagogues would improve insulin sensitivity in nondiabetic subjects at high risk of diabetes (impaired glucose tolerance), which are the focus of the current report, is not known.
In this study, we have a number of limitations. First, we have not directly measured insulin resistance or insulin sensitivity. Few studies have compared fasting insulin versus insulin resistance as a predictor of type 2 diabetes. Lillioja et al 14 showed that insulin resistance (as determined by hyperinsulinemic euglycemic clamp) was a better predictor than was fasting insulin, although both were strong predictors (hazard ratios of 30 and 15, respectively). Fasting insulin and ⌬I 30-0 /⌬G 30-0 have been correlated with more definitive methods for assessing insulin secretion and resistance. 28 -31 In the Mexico City Diabetes Study, HOMA IR was a slightly better predictor of the incidence of type 2 diabetes than were fasting insulin levels. 33 It is likely that more precise measurements of these variables would decrease misclassification and perhaps strengthen the present results.
In conclusion, we have shown that prediabetic subjects have an atherogenic pattern of cardiovascular risk factors, and these changes are predominantly observed in prediabetic subjects with increased HOMA IR and fasting insulin ("insulin resistance") at baseline. Insulin-sensitive converters to diabetes have a pattern of cardiovascular risk factors similar to nonconverters to diabetes. The most important possible implication of these findings is that different methods of preventing diabetes may have different effects on CHD, which is the most common cause of death in diabetic subjects. [1] [2] [3] 
